Phase 2 Stroke Trial, Recruiting NCT03255408 Sponsor: University of Calgary Condition: Stroke
Back to Stroke

Phase 2 Stroke Trial, Recruiting

NCT03255408
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults who are generally healthy with no significant medical conditions
  • People between 18 and 45 years of age
  • People who have been living in Calgary for at least the past one year
  • People who are not taking any blood pressure medications
  • People who are able to tolerate lactose (no lactose intolerance)

Who may not be able to join:

  • People who have conditions affecting the brain's blood vessels, heart, lungs, kidneys, or metabolism
  • People who have bleeding disorders or upper digestive tract conditions, such as peptic ulcers
  • People who are pregnant, considered obese, or have a sleep-related breathing condition such as sleep apnea
  • People who have an allergy to anti-inflammatory medications such as ibuprofen or aspirin
  • People who are currently smoking

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
University of Calgary
Registry
ClinicalTrials.gov
Start date
1 January 2023
Est. completion
30 December 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Changes in cerebral blood flow and ventilatory chemoreflexes; Cerebral blood flow responses and ventilatory chemoreflexes during sleep

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov